NGS-PTL

Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia

Coordinatore	ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA    more  Organization address address: Via Zamboni 33 city: BOLOGNA postcode: 40126 contact info Titolo: Dr. Nome: Valeria Cognome: Genovesi Email: send email Telefono: +39 051 20 99887
Nazionalità Coordinatore	Italy [IT]
Totale costo	7˙623˙351 €
EC contributo	5˙870˙815 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2015-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA  Organization address address: Via Zamboni 33 city: BOLOGNA postcode: 40126 contact info Titolo: Dr. Nome: Valeria Cognome: Genovesi Email: send email Telefono: +39 051 20 99887	IT (BOLOGNA)	coordinator	942˙941.56
2	PERSONAL GENOMICS SRL  Organization address address: STRADA LE GRAZIE 15 city: VERONA postcode: 37134 contact info Titolo: Prof. Nome: Massimo Cognome: Delledonne Email: send email Telefono: +39 045 8027962 Fax: 390458000000	IT (VERONA)	participant	795˙719.10
3	MLL MUNCHNER LEUKAMIELABOR GMBH  Organization address address: MAX LEBSCHE PLATZ 31 city: MUNCHEN postcode: 81377 contact info Titolo: Prof. Nome: Torsten Cognome: Haferlach Email: send email Telefono: +49 89 990 17 100 Fax: +49 89 990 17 109	DE (MUNCHEN)	participant	790˙450.00
4	FASTERIS SA  Organization address address: CHEMIN DU PONT DU CENTENAIRE 109 city: PLAN LES OUATES postcode: 1228 contact info Titolo: Dr. Nome: Laurent Cognome: Farinelli Email: send email Telefono: 41227942223	CH (PLAN LES OUATES)	participant	549˙400.00
5	UNIVERSITA DEGLI STUDI DI TORINO  Organization address address: Via Giuseppe Verdi 8 city: TORINO postcode: 10124 contact info Titolo: Dr. Nome: Massimiliano Cognome: Lauria Email: send email Telefono: +39 011 670 8428 Fax: +39 011 670 5731	IT (TORINO)	participant	546˙900.00
6	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Myriam Cognome: Witvrouw Email: send email Telefono: 3216320623 Fax: 3216326515	BE (LEUVEN)	participant	500˙002.72
7	SINAPTICA IT SRL  Organization address address: VIA COLLALTO SABINO 20 city: ROMA postcode: 199 contact info Titolo: Dr. Nome: Marco Cognome: Capoferri Email: send email Telefono: +39 3476126210	IT (ROMA)	participant	499˙400.00
8	UNIVERSITAET ULM  Organization address address: HELMHOLTZSTRASSE 16 city: ULM postcode: 89081 contact info Titolo: Mr. Nome: Frank Cognome: Gleixner Email: send email Telefono: +49731500 66397 Fax: +49731500 66392	DE (ULM)	participant	449˙600.00
9	FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA  Organization address address: Campus Miguel de Unamuno city: SALAMANCA postcode: 37007 contact info Titolo: Mr. Nome: Antonio Cognome: Mata Dominguez Email: send email Telefono: +34 923294720 Fax: +34 923294743	ES (SALAMANCA)	participant	399˙681.62
10	Masarykova univerzita  Organization address address: Zerotinovo namesti 9 city: BRNO STRED postcode: 60177 contact info Titolo: Dr. Nome: Katerina Cognome: Pejchalova Email: send email Telefono: +420 54949 4601	CZ (BRNO STRED)	participant	396˙720.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients. Nowadays, the advent of high-throughput next generation sequencing (NGS) technologies that are revolutionizing genomics and transcriptomics by providing a single base resolution tool for a unified deep analysis of diseases complexity allows a fast and cost-efficient fine-scale assessment of the genetic variability hidden within cohorts of patients affected by the same leukemia. That being so, by potentially highlighting inter-individual differences that may play a role in the differential success of diverse therapeutic interventions, they promise to be crucial for selecting the most appropriate medical treatments. This project aims at developing a European Hematological/NGS platform of scientists for improving outcomes for therapeutic interventions on acute and chronic leukemias and at developing strategies to personalize treatments and tailor therapies to different stratified groups of leukemia patients, with the goal of optimizing their efficacy and safety through a deeper and deeper understanding of the influence of genetic alterations on leukemias pathogenesis and treatment response (i.e. “personalized therapy”). Moreover, the final aim will be the identification of novel prognostic biomarkers for acute and chronic leukemias, as well as of molecular biomarkers and/or genome-wide profiles for the assessment of minimal residual disease. The originality of this project is to perform systematic deep whole exome/transcriptome studies on well-clinically-characterized leukemia patients, by exploiting NGS technologies able to quickly produce data with a good cost-effectiveness and an unprecedented resolution.'